以岭药业：子公司药品芪防鼻通片通过谈判纳入国家医保目录

Core Insights - Yiling Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yiling, has successfully negotiated for its exclusive product, Qifang Nasal Tablets, to be included in the National Medical Insurance Directory (2025 version) for the first time [1] - The drug is classified as a Category 1.1 traditional Chinese medicine, specifically for the treatment of persistent allergic rhinitis, with a reimbursement price set at 1.78 yuan per tablet, and the agreement is valid until December 31, 2027 [1] - In addition to Qifang Nasal Tablets, the company has 11 other exclusive products listed in the directory, which is expected to have a positive long-term impact on the company's operations, although the short-term impact on performance remains uncertain [1] Company Summary - Qifang Nasal Tablets have received registration approval from the National Medical Products Administration and a registration certificate for traditional Chinese medicine in Macau [1] - The inclusion of 12 products in the National Medical Insurance Directory is anticipated to enhance the company's long-term business prospects [1]